How Vertex Pharmaceuticals (VRTX) Makes Money: A Visual Guide
Vertex Pharmaceuticals (VRTX) generated $12.04B in revenue (TTM through Q4 2025), earning $3.95B in net profit (32.8% margin). Its largest revenue source is TRIKAFTA/KAFTRIO (86.2% of revenue). Below is an interactive breakdown of how revenue flows through the income statement.
Vertex Pharmaceuticals (VRTX) Income Statement Flow
Frequently asked questions
How does Vertex Pharmaceuticals (VRTX) make money?
- Vertex Pharmaceuticals (VRTX) primarily makes money through TRIKAFTA/KAFTRIO, which accounts for 86.2% of total revenue. For TTM through Q4 2025, Vertex Pharmaceuticals generated $12.04B in total revenue with a net profit margin of 32.8%.
What is Vertex Pharmaceuticals (VRTX) gross profit margin?
- Vertex Pharmaceuticals (VRTX) reported a gross profit margin of 86.3% for TTM through Q4 2025, equivalent to $10.39B in gross profit. This means Vertex Pharmaceuticals retains 86.3% of each revenue unit after direct costs of production.
What is Vertex Pharmaceuticals (VRTX) operating profit margin?
- Vertex Pharmaceuticals (VRTX) reported an operating profit margin of 35.5% for TTM through Q4 2025, equivalent to $4.27B in operating profit. This reflects profitability after operating expenses such as R&D, sales, and administration, but before taxes and non-operating items.
What is Vertex Pharmaceuticals (VRTX) net profit margin?
- Vertex Pharmaceuticals (VRTX) reported a net profit margin of 32.8% for TTM through Q4 2025, equivalent to $3.95B in net profit. This is the share of revenue that remains as profit after all expenses, taxes, and non-operating items.
How much does Vertex Pharmaceuticals (VRTX) invest in R&D?
- Vertex Pharmaceuticals (VRTX) invested $3.96B in research and development in TTM through Q4 2025 (32.9% of total revenue). R&D spending reflects investment in future products, services, and technologies.
How much does Vertex Pharmaceuticals (VRTX) spend on capital expenditures?
- Vertex Pharmaceuticals (VRTX) spent $437.60M on capital expenditures in TTM through Q4 2025 (3.6% of total revenue). Capital expenditures represent investments in physical assets such as property, equipment, and infrastructure.
What is Vertex Pharmaceuticals (VRTX) free cash flow?
- Vertex Pharmaceuticals (VRTX) generated $3.19B in free cash flow for TTM through Q4 2025 (26.5% of total revenue). Free cash flow is the cash remaining after capital expenditures and represents the company's ability to fund growth, pay dividends, or reduce debt.
What is Vertex Pharmaceuticals (VRTX) effective tax rate?
- Vertex Pharmaceuticals (VRTX) had an effective tax rate of 14.9% for TTM through Q4 2025. This is the actual percentage of pre-tax income paid as income taxes.
About this data
- What is a Sankey diagram?
- A Sankey diagram shows how money flows through a company from revenue to net profit. The width of each flow represents its proportion.
- How is the data calculated?
- We use the income statement from company filings. For TTM (Trailing Twelve Months), we sum the last four quarters. Revenue flows to cost of revenue and gross profit, then to operating expenses (R&D, S&M, G&A) and operating profit.
- When was this data last updated?
- Based on company filings through TTM through Q4 2025.